Peter Windisch Appointed Chief Technology Officer at Excelya
15.4.2021 10:03:00 EEST | Business Wire | Press release
Today, Excelya, the leading European contract research organization, has announced the appointment of Peter Windisch to the position of Chief Technology Officer (CTO). As CTO, Peter will aim to leverage data and technology to further optimize its client offer. He will be made a member of the Executive Committee and will be based in Germany.
Peter was most recently VP of Operations and Client Partner at PRA Health Sciences and has worked for decades in various leadership positions in health and technology. He began his career in health as a Manager of Information Technology and Data Management before moving up the ranks to Managing Director of various regions in Europe at IMEREM (now part of PRA Health Sciences) and ReSearch Pharmaceutical Services.
Alan Morgan, CEO of Excelya: “Excelya is investing heavily in technology to better support our clients and patients for the trials that we are managing. Innovation and efficiency are at the heart of what we do. This new position recognizes the importance of integrating different technology platforms to provide a seamless experience for our clients and patients.”
Peter Windisch, CTO of Excelya: “I am excited to join Excelya at this pivotal time as it deploys new technologies and develops new services. The Covid-19 crisis has helped the industry accelerate innovation to deliver results in record time. I look forward to being a part of this movement through Excelya’s rapidly expanding capabilities.”
About Excelya
Excelya is an independent European contract research organization with over 800 employees in 24 countries spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005375/en/
Contact information
Amélie Janson, Communications Director
ajanson@excelya.com / +33 6 47 87 31 41
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
